Needham & Company
-
Needham Reiterates Hold Rating on Teleflex (TFX)
-
Teleflex stock drops following Needham’s downgrade
-
Needham & Company Downgrades Teleflex (TFX) to Hold; 'UroLift Expectations May Still Be Too High'
-
Teleflex (TFX) PT Lowered to $425 at Needham & Company
-
Companies with NDRs 5/27
-
Companies with NDRs 3/05
-
Teleflex (TFX) PT Raised to $431 at Needham & Company, Following Earnings
-
Teleflex (TFX) PT Raised to $423 at Needham & Company
-
Teleflex (TFX) PT Rises To $408 At Needham After UroLift Drives Revenue and EPS Upside
-
Needham & Company Downgrades Teleflex (TFX) to Buy
-
Teleflex (TFX) PT To $325 At Needham On Organic Growth Accelerating
-
Needham & Company Upgrades Teleflex (TFX) to Strong Buy
-
Teleflex (TFX) PT Lowered to $279 at Needham & Company
-
Teleflex (TFX) PT Raised to $298 at Needham & Company
-
Teleflex (TFX) PT Raised to $293 at Needham & Company
-
Teleflex to Present at Needham & Company’s 17th Annual Healthcare Conference
-
Teleflex (TFX) PT Raised to $228 at Needham & Company Following 2Q
-
Teleflex (TFX) PT Raised to $224 at Needham & Company; 'Solid 1Q17 Results, Vascular Solutions Growth Remained Strong'
-
Needham & Company Starts Teleflex (TFX) at Buy

